Description: Axonics, based in Irvine, CA, has developed an innovative rechargeable implantable SNM system (r-SNM™) for the treatment of patients with OAB, FI, and UR. The Company’s proprietary r-SNM system is designed to be 60% smaller than existing technology and to last approximately 15 years. Axonics currently has marketing approvals in Europe, Canada, and Australia for OAB, FI, and UR.
Home Page: www.axonics.com
AXNX Technical Analysis
26 Technology Drive
Irvine,
CA
92618
United States
Phone:
949 396 6322
Officers
| Name | Title |
|---|---|
| Mr. Raymond W. Cohen | CEO & Director |
| Mr. Danny L. Dearen | Pres & CFO |
| Mr. Rinda K. Sama | Chief Operating Officer |
| Dr. John Woock Ph.D. | Exec. VP, Chief Marketing & Strategy Officer |
| Mr. Alfred J. Ford Jr. | Chief Commercial Officer |
| Mr. Guangqiang Jiang Ph.D. | Chief Technology Officer |
| Mr. Neil Bhalodkar | VP of Investor Relations |
| Mr. Aaron Pettit | Gen. Counsel & Chief Compliance Officer |
| Mr. Michael V. Williamson Esq., J.D. | Sr. VP, Gen. & IP Counsel |
| Dr. Karen L. Noblett M.A.S., M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.8046 |
| Price-to-Sales TTM: | 12.2448 |
| IPO Date: | 2018-10-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 517 |